FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to novel crystalline forms I, II and amorphous form of {4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5-yl}acetic acid.
EFFECT: invention relates to pharmaceutical composition, containing crystalline form I of compound and to application of crystalline form I for treatment, prevention or relief of one or more symptoms of disease, mediated by CRTH2, associated with eosinophils, basophils, where disease is selected from asthma, allergic asthma, asthma, induced by physical effort, allergic rhinitis, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity.
16 cl, 11 dwg, 8 tbl,11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AMINE SALTS OF CRTH2 ANTAGONIST | 2008 |
|
RU2468013C2 |
| 2-S-BENZYLSUBSTITUTED PYRIMIDINES AS CRTH2 ANTAGONISTS | 2008 |
|
RU2491279C2 |
| ALKYLTHIOPYRIMIDINES AS CRTH2 ANTAGONISTS | 2008 |
|
RU2491280C2 |
| DERIVATIVES OF IMIDAZO[1,2-C]PYRIMIDINYL ACETIC ACID | 2005 |
|
RU2373208C2 |
| CRYSTALLINE FORMS OF MAGL INHIBITOR | 2017 |
|
RU2799564C2 |
| BICYCLIC HETEROCYCLIC COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | 2006 |
|
RU2426733C2 |
| COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY | 2009 |
|
RU2503672C2 |
| PRODRUGS OF PYRIDONAMIDES USED AS MODULATORS OF SODIUM CHANNELS | 2014 |
|
RU2692766C1 |
| POLYMORPHIC FORM OF [5-FLUORINE-3-({ 2-[(4-FLUOROBENZENE) SULFONYL]PYRIDINE-3-YL} METHYL)-2-METHYLINDOLE-1-YL]-ACETIC ACID | 2015 |
|
RU2751319C2 |
| PYRIDONAMIDE PRODRUGS USED AS SODIUM CHANNELS MODULATORS | 2014 |
|
RU2811402C2 |
